EF- markedsføringstilladelsen vedrørende Tasmar (tolcapon), der oprindelig var tilladt til supplerende behandling af Parkinsons sygdom, blev suspenderet, fordi det var blevet klart, at fordelene ikke opvejede de risici, der var forbundet med brugen.
The Community marketing authorisation for Tasmar (tolcapone), originally authorised for adjunctive treatment of Parkinson’ s disease, was suspended because it became apparent that its benefits did not outweigh the risks of use.